Amorphex Therapeutics

Amorphex is developing TODDD™, a soft, patented device that corrects the inaccurate and inefficient delivery, poor compliance and excessive side effects that undermine current topical ocular pharmaceuticals. Topical drug delivery is critical in the treatment of many ophthalmic diseases including glaucoma, one of the leading causes of irreversible blindness in the world.

P1000433(1)



Amorphex Therapeutics has its primary laboratory and work space at the Massachusetts Medical Device Development (M2D2) Center at the University of Massachusetts-Lowell.



 


Copyright 2012-2017